Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
Open Access
- 9 March 2016
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 34 (3) , 290-299
Abstract
Summary: Background IMGN901 is a CD56-targeting antibody-drug conjugate designed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1 study investigated the safety, tolerability, pharmacokinetics, and preliminary activity of IMGN901 in patients with CD56-expressing solid tumors. Methods Patients were enrolled in cohorts of escalating IMGN901 doses, administered intravenously, on 3 consecutive days every 21 days. A dose-expansion phase accrued patients with small cell lung cancer (SCLC), Merkel cell carcinoma (MCC), or ovarian cancer. Results Fifty-two patients were treated at doses escalating from 4 to 94 mg/m2/day. The maximum tolerated dose (MTD) was determined to be 75 mg/m2. Dose-limiting toxicities included fatigue, neuropathy, headache or meningitis-like symptoms, chest pain, dyspnea, and myalgias. In the dose-expansion phase (n = 45), seven patients received 75 mg/m2 and 38 received 60 mg/m2 for up to 21 cycles. The recommended phase 2 dose (RP2D) was established at 60 mg/m2 during dose expansion. Overall, treatment-emergent adverse events (TEAEs) were experienced by 96.9 % of all patients, the majority of which were Grade 1 or 2. The most commonly reported Grade 3 or 4 TEAEs were hyponatremia and dyspnea (each 8.2 %). Responses included 1 complete response (CR), 1 clinical CR, and 1 unconfirmed partial response (PR) in MCC; and 1 unconfirmed PR in SCLC. Stable disease was seen for 25 % of all evaluable patients who received doses ≥60 mg/m2. Conclusions The RP2D for IMGN901 of 60 mg/m2 administered for 3 consecutive days every 3 weeks was associated with an acceptable tolerability profile. Objective responses were observed in patients with advanced CD56+ cancers.Keywords
This publication has 28 references indexed in Scilit:
- Merkel Cell Carcinoma: The Past, the Present, and the FutureJournal of Skin Cancer, 2013
- Merkel cell carcinoma: high recurrence rate despite aggressive treatmentJournal of Surgical Research, 2012
- CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfallsGynecologic Oncology, 2007
- Adjuvant Radiation Therapy Is Associated With Improved Survival in Merkel Cell Carcinoma of the SkinJournal of Clinical Oncology, 2007
- A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or EsophagusClinical Cancer Research, 2006
- CD56 staining in Merkel cell carcinoma and natural killer‐cell lymphoma: magic bullet, diagnostic pitfall, or both?Journal of Cutaneous Pathology, 2005
- Quality assurance in medical oncology within the EORTCEuropean Journal of Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small‐cell lung carcinoma and neuroblastomaInternational Journal of Cancer, 1989
- Neural Cell Adhesion Molecule: Structure, Immunoglobulin-Like Domains, Cell Surface Modulation, and Alternative RNA SplicingScience, 1987